Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-3,020.3%+46,549pp-6,714.8%+25,899pp-31,130.2%-1,605pp-30,392.2%-10,324pp-49,569.7%-36,998pp
Net margin-2,747.2%+40,444pp-6,046.2%+22,674pp-27,563.3%-815pp-26,568.5%-7,901pp-43,191.1%-31,263pp
Returns
Return on equity-39.2%-8.3pp-40.2%-8.1pp-44.4%-4.2pp-36.9%+10.7pp-30.8%+9.9pp
Return on invested capital-45.1%-1.8pp-50.4%-9.3pp-60.6%-0.7pp-48.4%+21.2pp-43.3%+20.9pp
Efficiency
Asset turnover0.0×0.0×0.0×0.0×0.0×
Liquidity
Current ratio18.6×-3.9×12.3×-10.7×15.1×-1.3×17.8×+1.7×22.5×+4.8×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$12.30-8.7%$10.55-35.7%$11.38+9.4%$12.49+18.8%$13.47+11.3%
Valuation
Market capitalization$3.8B+21.9%$4.42B-6.8%$3.92B-4.1%$2.9B-17.9%$3.12B-14.4%
Price / sales210.5×-3,896×574×-3,990×2,555.3×-1,381×2,082.2×-468×4,106.4×+2,258×
Price / book+0.5×4.5×+0.9×3.7×-1.3×2.5×-1.8×2.5×-1.7×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Crinetics Pharmaceuticals's profit margins?
Crinetics Pharmaceuticals (CRNX) runs a 150.0% gross margin and a -3020.3% operating margin, with a -2747.2% net margin.
Where do Crinetics Pharmaceuticals's ratios come from?
Every ratio is computed from Crinetics Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.